Interview with Igor Varlamov, CEO, Binnopharm
Binnopharm was established in 2006, with 100% of charter capital coming from holding company JSFC Sistema. What was the vision behind the creation of Binnopharm? The company was indeed established…
Address: 124460, г. Москва, г. Зеленоград, 4-й Западный проезд, дом 3, строение 1,Russia
Tel: +7 (495) 510-3288
Closed Joint-Stock Company “Binnopharm” (Moscow, Zelenograd) is formed with a 100% charter capital belonging to JFC Sistema with investment volume more than 4.3 bln RUR (50% in CAPEX).
CJSC “Binnopharm” is CJSC “Binnopharm” with its productive area more than 32 thous м2 is one of the most large-scaled biopharmaceutical companies in Russia. Biotechnological and pharmaceutical complex “Binnopharm” has the largest in Russia biotech medicines manufacture with complete production cycle. Production is built according to GMP (Good Manufacturing Practice) quality standards. Company also has a unique biotech Research & Development center. “Binnopharm” complex is fully equipped with multipurpose production lines provided by top international players for the full-cycle production of biotech medicines like: tablets, capsules, ampoules, sprays and environment friendly aerosols.
Top-priority course for the company’s activities is focused on developing and commercial availability of medicines across socially significant diseases such as oncology, hematology, infections and respiratory ones, genetically engineered medicines, vaccines and fibroblast-tissue technologies’ products in regenerative medicine.
CJSC “Binnopharm” is the founder and the basis of the Moscow nanobiopharmaceutical cluster “Biocity” that is located on the territory of Moscow Special Economic Zone “Zelenograd” – industrial technology park specialized in developing and implementation of innovating medicines as well as allocation of the best western elaborations and technologies on the territory of Russia.
Activity of «Binnopharm» Company aims at production of innovative medical aids that meet GMP international standards and implementation of an import replacement program. Here are set production lines for releasing of basic dosage forms: pills, capsules, vials and ecologically safe aerosols. «Binnopharm» is also a distributor of pharmaceutical substances and off-the-shelf dosage forms.
Biotechnology and genetic engineering have special status in the activity of «Binnopharm» Company. The enterprise possesses a unique full-cycle biotechnological production in Russia, with the most integrated and equipped laboratory for biotechnological preparation quality control. Here is produced a vaccine against the viral Hepatitis B – Regevac B.
Vaccine «Regevac B» produced now by «Binnopharm» CJSC, as to its properties, meets the World Health Organization’s requirements, and it is not inferior to, and upon certain indicators – leaves behind the foreign analogs. It is the most efficient and expedient recombinant vaccine for use in the territory of the Russia, produced on the basis of Hepatitis B virus’ strain, serotype ay.
Basic therapeutic groups of preparations, the production of which is projected in the new «Binnopharm» complex, are: haematology, oncology, infectious diseases, and respiratory diseases. Underway is development of biotechnological preparations that have principally new therapeutic opportunities, including treatment of diseases incurable in the past (cancer, AIDS, disseminated sclerosis), as well as new transport nanoforms. The Company’s production line has been continuously expanding.
Binnopharm was established in 2006, with 100% of charter capital coming from holding company JSFC Sistema. What was the vision behind the creation of Binnopharm? The company was indeed established…
You founded Euroservice, and have managed this business since its inception in 1996. What are the key drivers that have facilitated the growth of this company from a staff of…
In spring of 2010, Protek became the first Russian wholesaler to enter the public stock market, raising $400Mn in the biggest Russian IPO since 2007. You offered the IPO directly…
PAREXEL prides itself on improving the time schedule of a product launch. What is the significance of time-to-market in the healthcare industry, and how can PAREXEL expedite the process better…
Since our last report on Russia in 2007, there has been much emphasis placed on developing local industry, and reducing the nation’s reliance on imported pharmaceutical products. How do you…
You have been at your current position for less than a year, and joined BIOCODEX after having managed the Russian affiliate of Yves Saint Laurent. You have a long history…
You worked for ten years at Schering-Plough—one of the largest pharmaceutical companies in the world. In February of last year, you joined Merz Pharma, a much smaller player. Some may…
Russia and India have recently held a number of discussions regarding increased cooperation within the pharmaceutical sector. For example, the two nation’s health ministers have discussed decreasing administrative barriers to…
Biofund is an independent spin-off of the broader Russian Venture Capital organization. What is the working relationship and synergy between these agencies, and what are the market conditions that have…
Petrovax has always been an innovative company, making it quite unique in Russia where the domestic industry is predominantly comprised of generics manufacturers. How would you describe the positioning of…
After a long history in Philips, this is your first tenure as a regional CEO. Having been at this position for less than a year, what are your impressions of…
You were a Russian manager from 1996-2004, departed to Germany for some time, and recently made your way back to Russia in 2010. How has Russian healthcare and industry changed,…
You were responsible for merging Pierre Fabre’s activities in Russia in 2008, and heading the new legal entity and 100% subsidiary. What is it like to set up a new…
See our Cookie Privacy Policy Here
